Analyst: Vivus generic threats a positive for obesity market
20 April 2015
No drugmaker wants a generic challenger for a product it relies on--and certainly not two generics challengers. But in the case of Vivus ($VVUS), which has sued Actavis ($ACT) and now Teva ($TEVA) over patent infringement for weight-loss drug Qsymia, the generic interest could be an "incremental positive," one analyst believes.
Big orphan ante: MIT professor refines megafund idea to lure investors
17 April 2015
The prospect of establishing a specially focused orphan drug megafund, through which investors put money down and collect on the spoils as drugs and intellectual property rights are sold to venture capitalists or pharma firms, is one due to be explored during a panel talk at the Allicense 2015 conference by Andrew Lo, Sloan professor of finance at the Massachusetts Institute of Technology (MIT).
Record new drug sales give a mega-boost to U.S. drug spending
17 April 2015
Given the flood of numbers on hepatitis C treatment costs, it's no surprise that U.S. drug spending took a leap last year. Given the news on specialty drug prices, it's also no surprise that the biggest share of that growth came in that category of medications.
NIH awards $11M to develop tests for drug-resistant bacteria
17 April 2015
The U.S. National Institutes of Health is funneling more than $11 million toward 9 research programs developing rapid diagnostics for antimicrobial resistance, a week after the Obama administration announced a plan to prioritize point-of-care testing to curtail the rise of drug-resistant bacteria.
Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells
16 April 2015
Epic Sciences announced today that its no cell left behind™ technology has successfully integrated single cell isolation and downstream genetic analysis of circulating tumor cells (CTCs) to the platform's capabilities.
WHO demands disclosure of all clinical trial results
16 April 2015
The World Health Organization called on Tuesday for the release of clinical trial results for all drugs, vaccines and medical devices - whatever the result - in the latest salvo against the withholding of data.
More Evidence that Size Matters
16 April 2015
Size has proven to be a major competitive advantage in the clinical contract research organization (CRO) industry, and if that experience is any guide, it presages how the dose CMO industry will evolve as well.
Specialty, generic drug costs drive Medicaid costs up
16 April 2015
The high cost of a drug used to treat Medicaid patients with hepatitis C drew scrutiny from lawmakers earlier this year, but other drugs are also driving up the state's costs and likely will continue to do so for several years, government data reveals.
Vaccine to prevent two meningitis types at once developed in Bashkortostan
16 April 2015
Scientists in Ufa, in the Volga region of Bashkortostan, have come up with a combined vaccine for two different types of meningitis, the website of the Vesti TV channel reported . There have traditionally been separate vaccines for each of the types.
Atlas Genetics Enters Into Diagnostic Collaboration With a Major Pharmaceutical Company
15 April 2015
Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024